할로페리돌
|
|
할로페리돌 속성
- 녹는점
- 152 °C
- 끓는 점
- 529.0±50.0 °C(Predicted)
- 밀도
- 1.1820 (estimate)
- 인화점
- 9℃
- 저장 조건
- 2-8°C
- 용해도
- 45%(w/v) 수성 2-히드록시프로필-β-시클로덱스트린: 0.39mg/mL
- 물리적 상태
- 가루
- 산도 계수 (pKa)
- 8.3(at 25℃)
- 색상
- 하얀색
- 수용성
- 2.058mg/L(22.5℃)
- Merck
- 14,4598
- BCS Class
- 4/3
- CAS 데이터베이스
- 52-86-8(CAS DataBase Reference)
- NIST
- Haloperidol(52-86-8)
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
위험품 표기 | T,F | ||
---|---|---|---|
위험 카페고리 넘버 | 60-61-25-36/37/38-43-39/23/24/25-23/24/25-11 | ||
안전지침서 | 53-26-36/37/39-45-36/37-16 | ||
유엔번호(UN No.) | UN 2811 6.1/PG 3 | ||
WGK 독일 | 3 | ||
RTECS 번호 | EU1575000 | ||
위험 등급 | 6.1(b) | ||
포장분류 | III | ||
HS 번호 | 2933399090 | ||
유해 물질 데이터 | 52-86-8(Hazardous Substances Data) | ||
독성 | LD50 orally in rats: 165 mg/kg (Goldenthal); i.p. in mice: 60 mg/kg (Collins, Horlington) | ||
기존화학 물질 | KE-05840 |
할로페리돌 C화학적 특성, 용도, 생산
개요
Haloperidol is a butyrophenone with a long duration of action. It has lile α- adrenoceptor blocking activity and minimal effect on the cardiovascular system. It is an effective antiemetic but has a high incidence of extrapyramidal adverse effects. Haloperidol may be used in the short-term management of the acutely agitated patient (when sinister causes of confusion such as hypoxaemia and sepsis have been excluded) and in the management of delirium in ICU. The duration of action of haloperidol is approximately 24–48h.화학적 성질
White Crystalline Powder용도
Haloperidol is one of the most actively used modern neuroleptics. Its high antipsychotic activity is combined with a moderate sedative effect. It effectively stops various types of psychomotor excitement. It is used for schizophrenic psychoses, manic, paranoid, and delirious conditions, depression, psychomotor excitement of various origins, and for delirium and hallucinations of different origin.정의
ChEBI: A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.일반 설명
Haloperidol, 4-[4-(p-chlorophenyl)-4-hydroxypiperidino]-4-fluorobutyrophenone (Haldol), is anodorless white to yellow crystalline powder. Haloperidol iswell and rapidly absorbed and has a high bioavailability. It ismore than 90% bound to plasma proteins. Haloperidol is excretedslowly in the urine and feces. About 30% of a dose isexcreted in urine and about 20% of a dose in feces via biliaryelimination,and only 1% of a dose is excreted as unchangeddrug in the urine.Haloperidol is a minor substrate of CYP1A2 and a major substrate of CYP2D6 and CYP3A4.CYP2D6 inhibitors may increase the levels/effects ofhaloperidol.Haloperidol may increase the levels/effects ofCYP2D6 substrates and it may decrease the bioactivationof CYP2D6 prodrugs substrates. Haloperidol also is a moderateinhibitor of CYP2D6 and CYP3A4. CYP3A4 inducersmay decrease the levels/effects of haloperidol, whereasCYP3A4 inhibitors may increase the levels/effects ofhaloperidol. Centrally acting acetylcholinesterase inhibitorsmay increase the risk of antipsychotic-related EPS. The precisemechanism of antipsychotic action is unclear but isconsidered to be associated with the potent DA D2receptor–blocking activity in the mesolimbic system and theresulting adaptive changes in the brain. Haloperidol is usedprimarily for the long-term treatment of psychosis and is especiallyuseful in patients who are noncompliant with theirdrug treatment.Pharmaceutical Applications
Haloperidol is an analogue of the dopamine D2 receptor antagonist and is an older antipsychotic drug. The drug is used in the treatment of schizophrenia, a neuropsychiatric disorder. In general, antipsychotic drugs work by blocking the dopamine D2 receptors.Haloperidol is such an antipsychotic drug, which was developed in the 1950s and entered the clinic soon after that. Its use is limited by the high incidence of extrapyramidal symptoms (movement disorders caused by drugs affecting the extrapyramidal system, a neural network which is part of the motor system). Nevertheless, haloperidol may be used for the rapid control of hyperactive psychotic states and is popular for treating restlessness in the elderly.
생물학적 활성
Dopamine antagonist with selectivity for D 2 -like receptors (K i values are 1.2, ~ 7, 2.3, ~ 80 and ~ 100 nM for D 2 , D 3 , D 4 , D 1 and D 5 receptors respectively). Subtype-selective NMDA antagonist.할로페리돌 준비 용품 및 원자재
원자재
준비 용품
할로페리돌 공급 업체
글로벌( 394)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Xiamen Wonderful Bio Technology Co., Ltd. | +8613043004613 |
Sara@xmwonderfulbio.com | China | 305 | 58 |
Hangzhou FandaChem Co.,Ltd. | 008657128800458; +8615858145714 |
fandachem@gmail.com | China | 9332 | 55 |
Shanghai Yingrui Biopharma Co., Ltd. | +86-21-33585366 - 03@ |
sales03@shyrchem.com | CHINA | 738 | 60 |
SHANDONG ZHI SHANG CHEMICAL CO.LTD | +86 18953170293 |
sales@sdzschem.com | China | 2931 | 58 |
Hubei Jusheng Technology Co.,Ltd. | 18871490254 |
linda@hubeijusheng.com | CHINA | 28180 | 58 |
Shandong chuangyingchemical Co., Ltd. | 18853181302 |
sale@chuangyingchem.com | CHINA | 5909 | 58 |
CONIER CHEM AND PHARMA LIMITED | +8618523575427 |
sales@conier.com | China | 49391 | 58 |
career henan chemical co | +86-0371-86658258 +8613203830695 |
factory@coreychem.com | China | 29825 | 58 |
Hefei TNJ Chemical Industry Co.,Ltd. | 0551-65418671 |
sales@tnjchem.com | China | 34571 | 58 |
ANHUI WITOP BIOTECH CO., LTD | +8615255079626 |
eric@witopchemical.com | China | 23556 | 58 |
할로페리돌 관련 검색:
부틸디페닐클로로실란 트리틸클로라이드 부틸(노르말)벤젠 4-(4-염화페닐)-4-히드록시피페리딘 3-(4-플루오로벤조일)프로피오닉 산 메틸에틸케톤 할로페리돌
CHLOROPHOSPHONAZO III
CHLOROPHENYLSILANE 97
Chlorodimethylphenylsilane
trifluperidol
HALOPERIDOL DECANOATE
IOHEXOL IMPURITY J
IOHEXOL IMPURITY A
Diphenoxylate
5-Amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide
IOHEXOL RELATED COMPOUND C (100 MG) (N,N'- BIS(2,3-DIHYDROXYPROPYL)-5-NITRO-1,3-BENZENEDI- CARBOXAMIDE)
Iohexol